Asset Details
Do you wish to reserve the book?
VirB10 vaccination for protection against Anaplasma phagocytophilum
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
VirB10 vaccination for protection against Anaplasma phagocytophilum
Do you wish to request the book?
VirB10 vaccination for protection against Anaplasma phagocytophilum
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
VirB10 vaccination for protection against Anaplasma phagocytophilum
2018
Overview
Background
Human granulocytic anaplasmosis (HGA) is a tick-borne disease caused by the etiologic agent
Anaplasma phagocytophilum
. HGA was designated a nationally notifiable disease in the United States in 1998. Currently there are no vaccines available against HGA. Conserved membrane proteins that are subdominant in
Anaplasma
species, such as VirB9 and VirB10, may represent better vaccine targets than the variable immunodominant surface proteins. VirB9 and VirB10 are constituents of the Type 4 secretion system (T4SS) that is conserved amongst many intracellular bacteria and performs essential functions for invasion and survival in host cells.
Results
Immunogenicity and contribution to protection, provided after intramuscular vaccination of plasmid DNA encoding VirB9-1, VirB9-2, and VirB10 followed by inoculation of homologous recombinant proteins, in a prime-boost immunization strategy was evaluated in a murine model of HGA. Recombinant VirB9-1-, VirB9-2-, and VirB10-vaccinated mice developed antibody responses that specifically reacted with
A. phagocytophilum
organisms. However, only the mice vaccinated with VirB10 developed a significant increase in IFN-γ CD4
+
T cells and partial protection against challenge with
A. phagocytophilum
.
Conclusions
This work provides evidence that
A. phagocytophilum
T4SS VirB10 is partially protective in a murine model against infection in an IFN-γ-dependent fashion and suggests that this protein may be a potential vaccine candidate against this and possibly other pathogenic bacteria with a T4SS.
Publisher
BioMed Central,BioMed Central Ltd,Springer Nature B.V,BMC
Subject
/ Anaplasma phagocytophilum - genetics
/ Anaplasma phagocytophilum - immunology
/ Anaplasmosis - prevention & control
/ Animals
/ Antibodies, Bacterial - immunology
/ Bacteria
/ Bacterial Proteins - administration & dosage
/ Bacterial Proteins - genetics
/ Bacterial Proteins - immunology
/ Bacterial Vaccines - administration & dosage
/ Bacterial Vaccines - genetics
/ Bacterial Vaccines - immunology
/ Biomedical and Life Sciences
/ CD4-Positive T-Lymphocytes - immunology
/ Clinical microbiology and vaccines
/ DNA
/ Etiology
/ Female
/ Homology
/ Humans
/ Interferon-gamma - immunology
/ Mice
/ Mycology
/ Plasmids
/ Proteins
/ T4SS
/ Vaccines
/ Virology
